Cited by 33Medicinal Plants and NeuroprotectionAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Potential of Medicinal Plants as Neuroprotective and Therapeutic Properties Against Amyloid-β-Related Toxicity, and Glutamate-Induced Excitotoxicity in Human Neural Cells

Open access
Lobine, Devina, Sadeer, Nabeelah, Jugreet, Sharmeen, Suroowan, Shanoo, Keenoo, Bibi Sumera, Imran, Muhammad, Venugopala, Katharigatta N., Ibrahim, Faten Mohamed +2 more·2021·Current Neuropharmacology

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are notorious neurodegenerative diseases amongst the general population. Being age-associated diseases, the prevalence of AD and PD is forecasted to rapidly escalate with the progressive aging population of the world. These diseases are complex and multifactorial. Among different events, amyloid β peptide (Aβ) induced toxicity is a well-established pathway of neuronal cell death, which plays a vital function in AD. Glutamate, the major excitatory transmitter, acts as a neurotoxin when present in excess at the synapses; this latter mechanism is termed excitotoxicity. It is hypothesised that glutamate-induced excitotoxicity contributes to the pathogenesis of AD and PD. No cure for AD and PD is currently available and the currently approved drugs available to treat these diseases have limited effectiveness and pose adverse effects. Indeed, plants have been a major source for the discovery of novel pharmacologically active compounds for distinct pathological conditions. Diverse plant species employed for brain-related disorders in traditional medicine are being explored to determine the scientific rationale behind their uses. Herein, we present a comprehensive review of plants and their constituents that have shown promise in reversing the (i) amyloid-β -related toxicity in AD models and (ii) glutamate-induced excitotoxicity in AD and PD models. This review summarizes information regarding the phytochemistry, biological and cellular activities, and clinical trials of several plant species in view to provide adequate scientific baseline information that could be used in the drug development process, thereby providing effective leads for AD and PD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x19666210412095251

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many plant extracts showed multitarget effects in Alzheimer's disease treatment by addressing amyloid plaques, tau aggregation, oxidative stress, inflammation, cholinergic dysfunction, and excitotoxicity, while generally demonstrating safety and low toxicity or no toxicity in studies.

    “Moreover, many plant extracts showed multitarget effects in AD treatment by addressing amyloid plaques, tau aggregation, oxidative stress, inflammation, cholinergic dysfunction, and excitotoxicity, while generally demonstrating safety and low toxicity or no toxicity in studies [18,21,22].”

    From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [22]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [11]Jellinger K.A. Parkinson’s disease. Pathobiology of Human Disease. McManus L.M. Mitchell R.N. San Diego, US Academic Press 2014 2021 2035
  2. [19]Sun A.Y. Wang Q. Simonyi A. Sun G.Y. Botanical phenolics and neurodegeneration. 2015 22593921
  3. [72]Singh M. Neuroprotection: Pharmacological approaches. Encyclopedia of Neuroscience. Squire L.R. Oxford, UK Academic Press 2009 967 970
  4. [75]Piña-Crespo J.C. Sanz-Blasco S. Lipton S.A. Concept of excitotoxicity via glutamate receptors. Handbook of Neurotoxicity. Kostrzewa R. New York, US Springer 2014
  5. [96]Neta F.I. Da Costa I.M. Lima F.O.V. Fernandes L.C.B. De Paiva Cavalcanti J.R.L. De Moura Freire M.A. De Souza Lucena E.E. Do Rêgo A.C.M. De Azevedo E.P. Guzen F.P. Effects of Mucuna pruriens (L.) supplementation on experimental models of Parkinson’s disease: A systematic review. Pharmacogn. Rev. 2018 12 23

Cited by

Sorted by citations

Authors
Lobine, D., Sadeer, N., Jugreet, S., Suroowan, S., Keenoo, B. S., Imran, M., Venugopala, K. N., Ibrahim, F. M., Zengin, G., & Mahomoodally, M. F.
Affiliations
  • University of Mauritius (MU)
  • University of Lahore (PK)
  • King Faisal University (SA)
  • National Research Centre (EG)
  • Physiology and Biochemistry Research Laboratory, Department of Biology, Science Faculty, Selcuk University, Konya,Turkey
Corresponding author
Mahomoodally, Mohamad Fawzi
Venue
Current Neuropharmacology
Published
2021-09
Volume
19
Issue
9
Pages
1416-1441
ISSN
1570-159X (ISSN-L)
OpenAlex
W3154601305
Cited by
32
References
181
Citations by year
2026: 10 · 2025: 10 · 2024: 9 · 2023: 1 · 2022: 1 · 2021: 1
FWCI
3.37
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
medicinal plants, neuroprotection, amyloid-beta toxicity, glutamate excitotoxicity, Alzheimer's disease, Parkinson's disease, neurodegenerative diseases, phytochemistry, traditional medicine, phytochemicals, drug development
MeSH terms
Aged, Alzheimer Disease, Humans, Parkinson Disease, Plants, Medicinal, Amyloid beta-Peptides, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review